EClinical Medicine

Study published in EClinicalMedicine confirms safety and immunogenity of world’s first Needle-free COVID-19 DNA vaccine

Zydus Cadila (Cadila Healthcare Limited) published the results from their Phase I clinical study evaluating the safety and immunogenicity of their COVID-19 DNA vaccine, delivered using the PharmaJet Tropis Needle-free Injection System. The ZyCoV-D vaccine is comprised of plasmid DNA carrying the spike gene from SARS-CoV-2 and was initially evaluated in mouse, guinea pig, and…


Vaccine publishes independent survey showing overwhelming preference for Needle-free technology in large-scale intradermal polio vaccination campaign

The campaign, sponsored by the World Health Organization as part of its polio eradication efforts, vaccinated 500,000 children, aged 4 – 59 months, over a one-week period in early 2019.  Data on acceptability of the PharmaJet Tropis Needle-Free Injection System was collected from 610 vaccinators and 4,898 caregivers.  Of those with prior needle and syringe…

Study published in Clinical Cancer Research cites important progress towards new treatments for cancer using PharmaJet Tropis

Invectys published the results of their Phase I clinical trial testing their immune-therapeutic DNA cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system (Teixeira et al, 2019). The publication cites that “administration with the PharmaJet Tropis is immunogenic and able to elicit hTERT specific CD4 and CD8 immune responses in patients.

Study published in Viruses shows superior response with PharmaJet Tropis over electroporation

Bernelin-Cottet et al published a study that demonstrates the delivery of a DNA-based swine influenza vaccine with the PharmaJet Tropis Needle-free Jet Injector resulted in an increased cellular uptake as compared with administration via needle and syringe followed by electroporation. Importantly, administration by Tropis resulted in a non-inferior immune response, a more efficient cell uptake, and an equal potency to elicit an anti-Neuraminidase IgG response.

PharmaJet receives Frost & Sullivan Best Practices Award

Immunization coverage is critical to eradicating potentially deadly diseases while reducing the burden of disease. Safe, cost-effective, and patient-friendly injectable drug delivery systems play a crucial role in the success of global vaccination programs. PharmaJet leverages innovative jet injection technology to offer a needle-free, accurate, and more comfortable method of vaccine delivery. With unparalleled ease-of-use…

Needle-free Injection – Eradicating Diseases to Improve Global Health

Needle-free Injection technology has evolved significantly over the last 50 years and is now accepted in many routine immunization settings as a safe and effective vaccine delivery method. Disposable syringe jet injectors are now being used for the delivery of vaccines to eradicate polio, MMR, and influenza, and are showing promising results in vaccine clinical…

Clinical study published in Vaccine cites superiority of two fractional doses administered intradermally to one full intramuscular dose. Expands use of PharmaJet Tropis Needle-free Injector

The polio eradication endgame strategic plan calls for the sequential removal of Sabin poliovirus serotypes from the trivalent oral poliovirus vaccine (tOPV), starting with type 2, and the introduction of ≥1 dose of inactivated poliovirus vaccine (IPV), to maintain an immunity base against poliovirus type 2.